<p>Oculis（纳斯达克代码：OCS - 获取免费报告）于周四发布了季度财报。该公司报告本季度每股收益为（$0.59），低于分析师一致预期的（$0.53），差距为（$0.06），据 Zacks 报道。该季度的收入为 25 万美元，而分析师预期为 14 万美元。Oculis 的净利润率为负的 13,788.70%，股本回报率为负的 92.95%。</p>
<h2>Oculis 股票上涨 1.4%</h2>
<p>Oculis 股票周五开盘价为$17.80。Oculis 的 52 周最低价为$10.79，52 周最高价为$23.08。该公司的 50 日移动平均价格为$18.41，200 日移动平均价格为$18.74。该股票的市值为 7.7715 亿美元，市盈率为-6.74，贝塔值为 0.27。</p>
<h2>华尔街分析师观点</h2>
<p>多家研究分析师对 OCS 股票发布了报告。HC Wainwright 将 Oculis 的目标价格从$32.00 上调至$33.00，并在周五的研究报告中给予该公司 “买入” 评级。Chardan Capital 将 Oculis 的目标价格从$28.00 上调至$33.00，并在 5 月 9 日的研究报告中给予该公司 “买入” 评级。三位投资分析师对该股票给予了买入评级，根据 MarketBeat 的数据，该股票的平均评级为 “买入”，平均目标价格为$35.67。</p>
<p><strong>查看我们对 Oculis 的最新股票分析</strong></p>
<h2>对 Oculis 的对冲基金观点</h2>
<p>几家机构投资者最近买入和卖出了该公司的股票。Marshall Wace LLP 在第二季度购买了 Oculis 的新股份，价值$393,000。Geode Capital Management LLC 在第二季度将其在 Oculis 的股份增加了 27.7%。Geode Capital Management LLC 现在拥有 29,436 股该公司的股票，价值$571,000，在上个季度额外购买了 6,384 股。最后，Bank of America Corp DE 在第二季度将其在 Oculis 的股份增加了 2.2%。Bank of America Corp DE 现在拥有 40,512 股该公司的股票，价值$786,000，在上个季度额外购买了 878 股。对冲基金和其他机构投资者持有该公司 22.30% 的股份。</p>
<h2>Oculis 公司简介</h2>
<p>（获取免费报告）</p>
<p>Oculis Holding AG 是一家临床阶段的生物制药公司，开发用于治疗眼科疾病的药物候选者。该公司的主要产品候选者是 OCS-01，一种局部地塞米松 optireach 制剂，目前正在进行针对糖尿病性黄斑水肿的第三阶段临床试验；OCS-02，一种局部生物制剂候选者，目前正在进行针对干眼症的第二阶段临床试验；以及 OCS-05，一种用于神经损伤的疾病修饰神经保护剂，适应症包括青光眼、干性年龄相关性黄斑变性和糖尿病视网膜病变，以及急性视神经炎。</p>
<h2>进一步阅读</h2>
<ul>
<li>我们更看好的五只股票比 Oculis 更好</li>
<li>消费者价格指数测量什么？</li>
<li>博通被纳入苹果 1000 亿美元的美国投资计划</li>
<li>黄金交叉股票：模式、示例和图表</li>
<li>Salesforce 为何现在是一个便宜的选择的三个理由</li>
<li>如何从价值投资中获利</li>
<li>ServiceNow 如何将 AI 战略转化为实际收入</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9T0NT?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9T0NT"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对本故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资$1,000 在 Oculis 吗？</h2>
<p>在考虑 Oculis 之前，你会想听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐现在购买，以便在更广泛的市场注意到之前……而 Oculis 并不在名单上。</p>
<p>虽然 Oculis 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

<p>Oculis（纳斯达克代码：OCS）报告的季度每股收益为（$0.59），低于预期$0.06。该公司的收入为 25 万美元，超过了 14 万美元的预期。Oculis 的股本回报率为负 92.95%，净利润率为负 13,788.70%。尽管收益未达预期，Oculis 的股价仍上涨 1.4%，至 17.80 美元。分析师维持 “买入” 评级，目标价格范围为 32.00 美元至 35.67 美元。机构投资者持有该公司 22.30% 的股份，显示出对该公司的兴趣</p>

<p>Oculis (NASDAQ:OCS - Get Free Report) released its quarterly earnings results on Thursday. The company reported ($0.59) earnings per share for the quarter, missing analysts' consensus estimates of ($0.53) by ($0.06), Zacks reports. The business had revenue of $0.25 million for the quarter, compared to analyst estimates of $0.14 million. Oculis had a negative net margin of 13,788.70% and a negative return on equity of 92.95%.</p>
<div class="lb-trans"><p>Oculis（纳斯达克代码：OCS - 获取免费报告）于周四发布了季度财报。该公司报告本季度每股收益为（$0.59），低于分析师一致预期的（$0.53），差距为（$0.06），据 Zacks 报道。该季度的收入为 25 万美元，而分析师预期为 14 万美元。Oculis 的净利润率为负的 13,788.70%，股本回报率为负的 92.95%。</p>
</div><h2>Oculis Stock Up 1.4%</h2>
<div class="lb-trans"><h2>Oculis 股票上涨 1.4%</h2>
</div><p>Oculis stock opened at $17.80 on Friday. Oculis has a 52 week low of $10.79 and a 52 week high of $23.08. The company's 50 day moving average price is $18.41 and its two-hundred day moving average price is $18.74. The stock has a market cap of $777.15 million, a P/E ratio of -6.74 and a beta of 0.27.</p>
<div class="lb-trans"><p>Oculis 股票周五开盘价为$17.80。Oculis 的 52 周最低价为$10.79，52 周最高价为$23.08。该公司的 50 日移动平均价格为$18.41，200 日移动平均价格为$18.74。该股票的市值为 7.7715 亿美元，市盈率为-6.74，贝塔值为 0.27。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>华尔街分析师观点</h2>
</div><p>A number of research analysts have issued reports on OCS shares. HC Wainwright boosted their target price on Oculis from $32.00 to $33.00 and gave the company a &#34;buy&#34; rating in a research note on Friday. Chardan Capital upped their target price on Oculis from $28.00 to $33.00 and gave the company a &#34;buy&#34; rating in a research report on Friday, May 9th. Three investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the stock has an average rating of &#34;Buy&#34; and an average target price of $35.67.</p>
<div class="lb-trans"><p>多家研究分析师对 OCS 股票发布了报告。HC Wainwright 将 Oculis 的目标价格从$32.00 上调至$33.00，并在周五的研究报告中给予该公司 “买入” 评级。Chardan Capital 将 Oculis 的目标价格从$28.00 上调至$33.00，并在 5 月 9 日的研究报告中给予该公司 “买入” 评级。三位投资分析师对该股票给予了买入评级，根据 MarketBeat 的数据，该股票的平均评级为 “买入”，平均目标价格为$35.67。</p>
</div><p><strong>Check Out Our Latest Stock Analysis on Oculis</strong></p>
<div class="lb-trans"><p><strong>查看我们对 Oculis 的最新股票分析</strong></p>
</div><h2>Hedge Funds Weigh In On Oculis</h2>
<div class="lb-trans"><h2>对 Oculis 的对冲基金观点</h2>
</div><p>Several institutional investors have recently bought and sold shares of the company. Marshall Wace LLP bought a new stake in shares of Oculis during the 2nd quarter valued at $393,000. Geode Capital Management LLC increased its stake in Oculis by 27.7% in the second quarter. Geode Capital Management LLC now owns 29,436 shares of the company's stock valued at $571,000 after acquiring an additional 6,384 shares during the last quarter. Finally, Bank of America Corp DE grew its stake in shares of Oculis by 2.2% during the second quarter. Bank of America Corp DE now owns 40,512 shares of the company's stock valued at $786,000 after buying an additional 878 shares during the last quarter. Hedge funds and other institutional investors own 22.30% of the company's stock.</p>
<div class="lb-trans"><p>几家机构投资者最近买入和卖出了该公司的股票。Marshall Wace LLP 在第二季度购买了 Oculis 的新股份，价值$393,000。Geode Capital Management LLC 在第二季度将其在 Oculis 的股份增加了 27.7%。Geode Capital Management LLC 现在拥有 29,436 股该公司的股票，价值$571,000，在上个季度额外购买了 6,384 股。最后，Bank of America Corp DE 在第二季度将其在 Oculis 的股份增加了 2.2%。Bank of America Corp DE 现在拥有 40,512 股该公司的股票，价值$786,000，在上个季度额外购买了 878 股。对冲基金和其他机构投资者持有该公司 22.30% 的股份。</p>
</div><h2>Oculis Company Profile</h2>
<div class="lb-trans"><h2>Oculis 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.</p>
<div class="lb-trans"><p>Oculis Holding AG 是一家临床阶段的生物制药公司，开发用于治疗眼科疾病的药物候选者。该公司的主要产品候选者是 OCS-01，一种局部地塞米松 optireach 制剂，目前正在进行针对糖尿病性黄斑水肿的第三阶段临床试验；OCS-02，一种局部生物制剂候选者，目前正在进行针对干眼症的第二阶段临床试验；以及 OCS-05，一种用于神经损伤的疾病修饰神经保护剂，适应症包括青光眼、干性年龄相关性黄斑变性和糖尿病视网膜病变，以及急性视神经炎。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than Oculis</li>
<li>What does consumer price index measure?</li>
<li>Broadcom Named in Apple’s $100B U.S. Investment Plan</li>
<li>Golden Cross Stocks: Pattern, Examples and Charts</li>
<li>3 Reasons Salesforce Is a Bargain Right Now</li>
<li>How to Profit From Value Investing</li>
<li>How ServiceNow Is Turning AI Strategy Into Real Revenue</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 Oculis 更好</li>
<li>消费者价格指数测量什么？</li>
<li>博通被纳入苹果 1000 亿美元的美国投资计划</li>
<li>黄金交叉股票：模式、示例和图表</li>
<li>Salesforce 为何现在是一个便宜的选择的三个理由</li>
<li>如何从价值投资中获利</li>
<li>ServiceNow 如何将 AI 战略转化为实际收入</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9T0NT" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=OCS"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对本故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Oculis Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资$1,000 在 Oculis 吗？</h2>
</div><p>Before you consider Oculis, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Oculis 之前，你会想听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oculis wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐现在购买，以便在更广泛的市场注意到之前……而 Oculis 并不在名单上。</p>
</div><p>While Oculis currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Oculis 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Oculis（NASDAQ:OCS）公布季度财报结果，每股收益比预期低 0.06 美元